U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Flavour Warehouse LTD d/b/a Vampire Vape - 610057 - 09/09/2020
  1. Warning Letters

WARNING LETTER

Flavour Warehouse LTD d/b/a Vampire Vape MARCS-CMS 610057 —


Delivery Method:
VIA Electronic Mail
Product:
Tobacco

Recipient:
Recipient Name
Philip Boyle and Nathan Walton
Flavour Warehouse LTD d/b/a Vampire Vape

United Kingdom

wholesale@vampirevape.co.uk
customerservices@vampirevape.co.uk
Issuing Office:
Center for Tobacco Products

United States


WARNING LETTER

 

Dear Philip Boyle and Nathan Walton:

The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https://www.vampirevape.co.uk and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States. 

Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption.  Certain tobacco products, including ENDS, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1.  Therefore, ENDS products are required to be in compliance with the requirements in the FD&C Act.

Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act.  These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco.  See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https://federalregister.gov/a/2016-10685.

The FD&C Act requires “new tobacco products” to have premarket authorization.  A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)).  Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).

New Tobacco Products Without Required Marketing Authorization is Adulterated and Misbranded

Our review of the website https://www.vampirevape.co.uk revealed that you offer for sale or distribution to customers in the United States the following ENDS product without a marketing authorization order, for example: Ice Menthol – 10ml Vampire Vape E-Liquid.

 The ENDS product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007.  This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement.  Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act.  In addition, it is misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.

Additional Considerations

FDA finds the Ice Menthol – 10ml Vampire Vape E-Liquid particularly concerning because the product packaging features graphic images of cartoon vampires (see Exhibit A).  Such cartoon images are commonly marketed toward and/or appealing to children. FDA is concerned about the rising youth appeal and dramatic rise in youth use of ENDS products.  Sales of such products to individuals under the age of 21 are prohibited and any efforts to entice youth to use tobacco products, including marketing products with youth-appealing cartoons or animated characters, including vampires, are of concern to FDA.   FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.

Purple Top

.

Conclusion and Requested Actions

It is your responsibility to ensure that your tobacco products and all related labeling and/or advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may result in FDA taking regulatory action. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act.  Please note that adulterated and misbranded tobacco products offered for import into the United States are subject to detention and refusal of admission.

The violations discussed in this letter do not necessarily constitute an exhaustive list.  You should promptly correct the violations that are referenced above, as well as violations that are the same as or similar to those stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act. 

Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative labeling, advertising, sale, and/or distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act.  If you do not believe that your products are in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.  You can find the FD&C Act through links on FDA’s homepage at http://www.fda.gov.

Please note your reference number, RW2001417, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:

DPAL-WL Response, Office of Compliance and Enforcement
FDA Center for Tobacco Products
c/o Document Control Center
Building 71, Room G335
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.    

 

Sincerely,
/S/

Ann Simoneau, J.D.
Director
Office of Compliance and Enforcement
Center for Tobacco Products

 

VIA Electronic Mail

cc:

Flavour Warehouse LTD d/b/a Vampire Vape
Attn: Philip Boyle and Nathan Walton
contact@vampirevape.fr
orders@vampirevape.de
joe@oz-eliquid.com.au
office@esmoker.bg
info@ockglobal.com

Flavour Warehouse LTD
Attn: Philip Boyle
info@flavourwarehouse.co.uk

GoDaddy.com, LLC
abuse@godaddy.com

PSINet, Inc.
abuse@cogentco.com

 

Back to Top